Login / Signup

Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6-11 years with cystic fibrosis in a real-world setting.

Valeria DaccòChiara RosazzaAlessandra MarianiCarmela RizzaNicolò IngianniErica NazzariVito TerlizziFrancesco Arturo BlasiGianfranco Alicandro
Published in: Pediatric pulmonology (2024)
Our data indicate that ETI therapy is well tolerated by children with CF and is effective in improving signs of lung function abnormalities from early childhood.
Keyphrases
  • lung function
  • cystic fibrosis
  • young adults
  • chronic obstructive pulmonary disease
  • air pollution